5 Days, 5 SPAC IPOs for February as Hennessey Capital VIII and Cantor Equity Partners VI Launch. DT Coud Star Deal with Regenertive Medicine Company PrimeGen US.

Boardroom Alpha SPAC Resources
– Full SPAC Listing
– SPAC SEC Filings
– Boardroom Alpha IPO & SPAC Intelligence Platform (7-Day Trial)

TODAY’S SPAC IPOs

SPAC IPO: Hennessy Capital Investment Corp. VIII
Ticker: HCICU (Shares: HCIC, Rights: HCICR)
Size: $210 Million
Sponsor: HC VIII Sponsor LLC (Hennessy Capital Group)

Hennessy Capital Investment Corp. VIII priced its upsized $210 million IPO on February 4, 2026, and hits the Nasdaq today. This is the eighth vehicle from Daniel J. Hennessy’s prolific stable, arriving as the sponsor continues its aggressive deployment across industrial verticals. The team is currently navigating the pending merger of Hennessy VII with ONE Nuclear, following a busy 2025 that saw the de-SPAC of Namib Minerals. By upsizing from an initial $175 million target, Hennessy signals robust institutional appetite for veteran-led vehicles in a stabilizing deal environment.

Strategy: The SPAC is zeroing in on “Industrial Innovation” and the “Energy Transition” sectors. Management is hunting for targets with enterprise values exceeding $500 million, specifically eyeing businesses that facilitate decarbonization, sustainable infrastructure, or advanced manufacturing.

Leadership Team:

• Daniel J. Hennessy (Chairman & CEO): A central figure in the SPAC market since 2013, Hennessy has successfully steered 12 vehicles to business combinations, including marquee names like Blue Bird and Canoo.
• Nicholas Geeza (CFO): Head of Business Development at Hennessy Capital Growth Strategies, Geeza brings deep experience in capital allocation and sponsor-side execution.

Structure: 21 million units at $10.00. Each unit consists of one Class A ordinary share and one-twelfth (1/12) of one right. Each right entitles the holder to one-twelfth of a share upon the completion of a business combination. Notably, this structure excludes warrants entirely—a move increasingly favored by serial sponsors to streamline cap tables and avoid derivative accounting volatility. Barclays and Cohen & Company acted as joint book-runners.

SPAC IPO: Cantor Equity Partners VI, Inc.
Ticker: CEPS
Size: $100 Million
Sponsor: Cantor Fitzgerald & Co.

Cantor Equity Partners VI priced its $100 million IPO on February 4, 2026, and begins trading on the Nasdaq today. This marks the fifteenth blank-check vehicle launched by Howard Lutnick’s Cantor Fitzgerald, reinforcing the firm’s commitment to providing flexible capital despite a more selective broader market. Unlike many peers, this vehicle consists of common shares only—foregoing the traditional unit/warrant structure—which indicates a “clean” equity play designed for speed and simplicity in a potential merger.

Strategy: CEPS is sector-agnostic but explicitly leans into industries where Cantor holds significant proprietary deal flow: financial services, digital assets, healthcare, real estate, and software. The focus is on “high-moat” businesses with sustainable long-term growth prospects.

Leadership Team:

• Brandon G. Lutnick (Chairman & CEO): Leading this latest Cantor vehicle, Lutnick represents the next generation of the firm’s leadership, backed by the full weight of Cantor’s global distribution and investment banking platform.
• Jane Novak (CFO): A veteran executive within the Cantor ecosystem, Novak provides the institutional continuity required to manage the SPAC’s regulatory and financial lifecycle.

Structure: 10 million Class A ordinary shares at $10.00. The absence of warrants or rights makes this a rare “common stock only” SPAC, a structure that significantly reduces potential dilution for the eventual merger partner and simplifies the pro-forma equity valuation. Cantor Fitzgerald & Co. acted as the sole book-running manager.

SPAC DEALS ANNOUNCED

SPAC DEALS ANNOUNCED
Feb 04 | DTSQ – Dt Cloud Star Acquisition Corp + PrimeGen US, Inc

ABOUT PrimeGen US, Inc
PrimeGen US is a regenerative medicine company, leveraging nearly two decades of proprietary stem cell research to develop Triple Activated Mesenchymal Stem Cells (MSCs) as a novel, cell-based treatment for acute liver injury and related critical conditions. The Company’s platform has demonstrated in preclinical activity in animal studies, and recent advancements include completion of a Pre-Investigational New Drug application (Pre-IND) meeting for Acute Alcoholic Hepatitis (Acute Liver Failure) with the U.S. Food & Drug Administration (FDA) on December 17, 2025. There can be no assurance that the FDA will allow an IND to proceed or that any clinical trials will be successful, and preclinical results may not be indicative of clinical outcomes in humans. PrimeGen US is working toward the initiation of a clinical trial, subject to regulatory approval, to support further development of Triple Activated MSCs for the potential treatment of Acute Alcoholic Hepatitis (Acute Liver Failure).

DAILY SPAC UPDATE

SPAC NEWS
SBXD – SILVERBOX CORP IV * Investor Deck
FTW – EQV VENTURES ACQUISITION CORP * Media Transcript
SVAC – SPRING VALLEY ACQUISITION CORP III * Media Transcript

SEPARATE WARRANTS/RIGHTS
Feb 09: LAUNCHPAD CADENZA ACQUISITION CORP I (LPCV)
Feb 06: TGE VALUE CREATIVE SOLUTIONS CORP (BEBE)
Feb 04: LAFAYETTE DIGITAL ACQUISITION CORP I (ZKP)
Feb 02: BLUEROCK ACQUISITION CORP (BLRK)

SPAC LIQUIDATIONS
AA Mission Acquisition Corp. (AAM)-> Liquidation on Feb 13
Cartica Acquisition Corp (CITE)-> Liquidation on Feb 07

SEPARATE WARRANTS/RIGHTS
Feb 06: TGE VALUE CREATIVE SOLUTIONS CORP (BEBE)
Feb 04: LAFAYETTE DIGITAL ACQUISITION CORP I (ZKP)
Feb 02: BLUEROCK ACQUISITION CORP (BLRK)

SPAC DEAL TERMINATIONS (Last 10 Days)
2026-01-30: LPAA + Minovia Therapeutics Ltd

SPAC MOVERS

YESTERDAY’S TOP SPAC GAINERS
2.6% ~ $ 10.74 | TVA – TEXAS VENTURES ACQUISITION III CORP (Pre-Deal)
1.3% ~ $ 12.00 | KVAC – KEEN VISION ACQUISITION CORP (Announced)
1.2% ~ $ 10.05 | BBCQ – BLEICHROEDER ACQUISITION CORP II (Pre-Deal)
1.1% ~ $ 10.13 | LATA – GALATA ACQUISITION CORP II (Pre-Deal)
1.0% ~ $ 10.21 | OYSE – OYSTER ENTERPRISES II ACQUISITION CORP (Pre-Deal)

YESTERDAY’S TOP SPAC LOSERS
-11.4% ~ $ 12.69 | CCCX – CHURCHILL CAPITAL CORP X (Announced)
-10.1% ~ $ 13.11 | ASPC – ASPAC III ACQUISITION CORP (Announced)
-8.0% ~ $ 49.70 | AFJK – AIMEI HEALTH TECHNOLOGY CO LTD (Announced)
-4.4% ~ $ 13.39 | PCSC – PERCEPTIVE CAPITAL SOLUTIONS CORP (Pre-Deal)
-3.7% ~ $ 7.02 | RDAC – RISING DRAGON ACQUISITION CORP (Announced)

LATEST SPAC IPO PERFORMANCE
Feb 04 | CLBR – Colombier Acquisition Corp. III
Feb 03 | $ 9.96 | IRAB – Iris Acquisition Corp II
Feb 02 | $ 10.02 | WPAC – White Pearl Acquisition Corp
Jan 30 | $ 10.03 | MEVO – M Evo Global Acquisition Corp II
Jan 30 | TBD – Muzero Acquisition Corp
Jan 30 | $ 10.01 | NBRG – Newbridge Acquisition Ltd
Jan 29 | KII – K2 Capital Acquisition Corp
Jan 29 | $ 10.00 | UAC – United Acquisition Corp. I
Jan 29 | $ 9.92 | XSLL – Xsolla SPAC 1
Jan 28 | $ 10.11 | KRAQ – KRAKacquisition Corp
Jan 28 | $ 10.18 | SAAQ – Space Asset Acquisition Corp.
Jan 27 | $ 10.04 | GIX – GigCapital9 Corp.
Jan 27 | $ 10.00 | MLAA – Mountain Lake Acquisition Corp. II
Jan 23 | $ 10.01 | LEGO – Legato Merger Corp. IV
Jan 23 | HLXC – Helix Acquisition Corp. III
Jan 23 | $ 10.10 | ARCI – Archimedes Tech SPAC Partners III Co
Jan 23 | $ 10.00 | PTOR – Praetorian Acquisition Corp.
Jan 22 | $ 10.00 | ALOV – Aldabra 4 Liquidity Opportunity Vehicle, Inc.
Jan 21 | $ 10.00 | XCBE – X3 Acquisition Corp. Ltd.
Jan 16 | $ 10.00 | FGII – FG Imperii Acquisition Corp
Jan 16 | $ 10.22 | IEAG – Infinite Eagle Acquisition Corp.
Jan 14 | $ 10.11 | OIM – OneIM Acquisition Corp.
Jan 09 | $ 10.00 | ZKP – Lafayette Digital Acquisition Corp. I
Jan 08 | $ 10.14 | BBCQ – Bleichroeder Acquisition Corp. II
Jan 07 | $ 9.98 | SORN – Soren Acquisition Corp.
Jan 06 | $ 9.99 | ARTC – Art Technology Acquisition Corp.
Jan 06 | $ 10.17 | BIII – Black Spade Acquisition III Co
Jan 06 | $ 10.15 | BIII – Black Spade Acquisition III Co